Group Argues Sanders’ GLP-1 Price Estimate Omits Costs of Innovation

As Senate health committee Chair Bernie Sanders (I-VT) demands Novo Nordisk share pricing and sales data for its lucrative type-2 diabetes drugs, Wegovy and Ozempic, a think tank has released a report countering the Yale University report Sanders relied on in calculating the drugs cost less than $5 to produce, saying it doesn’t factor in the costs of creating an innovative medication. The California-based free market think tank Pacific Research Institute (PRI) released a report Wednesday (May 8) saying the...